12178 Federal Register / Vol. 72, No.
50 / Thursday, March 15, 2007 / Notices
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the review, discussion, and
evaluation of scientific merit of grant
applications received in response to RFA
DD07–006, ‘‘China-United States
Collaborative, Population-Based Surveillance
and Research Program for Maternal-Child
and Family Health.’’
For Further Information Contact: Juliana
Cyril, Ph.D., Scientific Review Administrator,
Centers for Disease Control and Prevention,
1600 Clifton Road NE, Mailstop D72, Atlanta,
GA 30333, Telephone 404.639.4639.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: March 8, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E7–4744 Filed 3–14–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Childhood
Agriculture Safety and Health
Research, Request for Applications
(RFA) OH 07–002
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting.
Time and Date: 1 p.m.–3 p.m., April
16, 2007 (Closed).
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
TABLE 1.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
No. of
21 CFR Section
Recordkeepers
589.2000(e)(1)(iv)
rmajette on PROD1PC67 with NOTICES
1There are no capital costs or operating and maintenance costs associated with this collection of information.
VerDate Aug<31>2005 14:20 Mar 14, 2007 Jkt 211001
Matters to be Discussed: The meeting
will include the review, discussion, and
evaluation of applications received in
response to RFA OH 07–002,
‘‘Childhood Agriculture Safety and
Health Research.’’
Contact Person For More Information:
Stephen Olenchock, Scientific Review
Administrator, Office of Extramural
Coordination and Special Projects,
National Institute for Occupational
Safety and Health, CDC, 1095
Willowdale Road, Mailstop P–04,
Morgantown, WV 26506, Telephone
304–285–6271.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
Elaine L. Baker,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E7–4745 Filed 3–14–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006N–0472]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Substances
Prohibited From Use in Animal Food or
Feed; Animal Proteins Prohibited in
Ruminant Feed
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
Annual Frequency
per Recordkeeping
400 1 400
PO 00000 Frm 00015 Fmt 4703 Sfmt 4703
DATES: Fax written comments on the
collection of information by April 16,
2007.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301– 827–
1472.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Substances Prohibited from Use in
Animal Food or Feed; Animal Proteins
Prohibited in Ruminant Feed—21 CFR
589.2000(e)(1)(iv) (OMB Control
Number 0910–0339)—Extension
This information collection was
established because epidemiological
evidence gathered in the United
Kingdom suggested that bovine
spongiform encephalopathy (BSE), a
progressively degenerative central
nervous system disease, is spread to
ruminant animals by feeding protein
derived from ruminants infected with
BSE. That regulation places general
requirements on persons that
manufacture, blend, process, and
distribute products that contain or may
contain protein derived from
mammalian tissue, and feeds made from
such products.
In the Federal Register of December 4,
2006 (71 FR 70409), FDA published a
60-day notice requesting public
comment on the information collection
provisions. No comments were received.
The respondents for this collection of
information are manufacturers and or
distributors of products that contain or
may contain protein derived from
mammalian tissues and feeds made
from such products.
Total Annual Hours per
Total Hours
Records Record
14 5,600
E:\FR\FM\15MRN1.SGM 15MRN1
 Federal Register / Vol. 72, No. 50 / Thursday, March 15, 2007 / Notices
Dated: March 7, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7–4685 Filed 3–14–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket Nos. 2006M–0384, 2006M–0385,
2006M–0386]
Medical Devices Regulated by the
Center for Biologics Evaluation and
Research; Availability of Summaries of
Safety and Effectiveness Data for
Premarket Approval Applications
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
SUMMARY: The Food and Drug
Administration (FDA) is publishing a
list of premarket approval applications
(PMAs) that have been approved by the
Center for Biologics Evaluation and
Research (CBER). This list is intended to
inform the public of the availability
through the Internet and the FDA’s
Division of Dockets Management of
summaries of safety and effectiveness
data of approved PMAs.
ADDRESSES: Submit written requests for
copies of summaries of safety and
effectiveness data to the Division of
TABLE 1.—LIST OF SUMMARIES OF SAFETY AND EFFECTIVENESS DATA FOR APPROVED PMAS MADE AVAILABLE MARCH
1, 2006, THROUGH JUNE 30, 2006
PMA No./Docket No.
BP050009/0/2006M–0384
BP050010/0/2006M–0385
TABLE 2.—LIST SUMMARIES OF SAFETY AND EFFECTIVENESS DATA FOR APPROVED PMAS MADE AVAILABLE JULY 1,
2006, THROUGH SEPTEMBER 30, 2006
PMA No./Docket No.
BP050030/0/2006M–0386
II. Electronic Access
Persons with access to the Internet
may obtain the documents at http://
www.fda.gov/cber/products.htm.
Dated: March 5, 2007.
rmajette on PROD1PC67 with NOTICES
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7–4677 Filed 3–14–07; 8:45 am]
BILLING CODE 4160–01–S
VerDate Aug<31>2005 14:20 Mar 14, 2007 Jkt 211001
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852.
Please include the appropriate docket
number as listed in tables 1 and 2 of this
document when submitting a written
request. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the summaries of safety and
effectiveness data.
FOR FURTHER INFORMATION CONTACT:
Nathaniel L. Geary, Center for Biologics
Evaluation and Research (HFM–17),
Food and Drug Administration, suite
200N, 1401 Rockville Pike, Rockville,
MD 20852–1448, 301–827–6210.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of January 30,
1998 (63 FR 4571), FDA published a
final rule that revised 21 CFR 814.44(d)
and 814.45(d)) to discontinue individual
publication of PMA approvals and
denials in the Federal Register,
providing instead to post this
information on the Internet at http://
www.fda.gov. In addition, the
regulations provide that FDA publish a
quarterly list of available safety and
effectiveness summaries of PMA
approvals and denials that were
announced during the quarter. FDA
believes that this procedure expedites
public notification of these actions
because announcements can be placed
on the Internet more quickly than they
can be published in the Federal
Applicant
Chembio Diagnostic Systems, Inc. SURE CHECK HIV 1/2 ASSAY
Chembio Diagnostic Systems, Inc. HIV 1/2 STAT–PAKT ASSAY
Applicant
Bayer Healthcare LLC ADVIA Centaur HIV 1/0/2 En-
hanced Assay
DEPARTMENT OF HOMELAND
SECURITY
National Communications System
[Docket No. NCS–2007–0001]
National Security Telecommunications
Advisory Committee
AGENCY: National Communications
System, DHS.
PO 00000 Frm 00016 Fmt 4703 Sfmt 4703
12179
Register, and FDA believes that the
Internet is accessible to more people
than the Federal Register.
In accordance with section 515(d)(4)
and (e)(2) of the Federal Food, Drug, and
Cosmetic Act (the act) (21 U.S.C.
360e(d)(4) and (e)(2)), notification of an
order approving, denying, or
withdrawing approval of a PMA will
continue to include a notice of
opportunity to request review of the
order under section 515(g) of the act.
The 30-day period for requesting
administrative reconsideration of an
FDA action under § 10.33(b) (21 CFR
10.33(b)) for notices announcing
approval of a PMA begins on the day the
notice is placed on the Internet. Section
10.33(b) provides that FDA may, for
good cause, extend this 30-day period.
Reconsideration of a denial or
withdrawal of approval of a PMA may
be sought only by the applicant; in these
cases, the 30-day period will begin
when the applicant is notified by FDA
in writing of its decision.
The following is a list of PMAs
approved by CBER for which summaries
of safety and effectiveness data were
placed on the Internet from March 1,
2006, through June 30, 2006, and from
July 1, 2006, through September 30,
2006. There were no denial actions
during either period. The list provides
the manufacturer’s name, the product’s
generic name or the trade name, and the
approval date.
Trade Name Approval Date
May 25, 2006
May 25, 2006
Trade Name Approval Date
May 18, 2006
ACTION: Notice of partially closed
advisory committee meeting.
SUMMARY: The President’s National
Security Telecommunications Advisory
Committee (NSTAC) will be meeting by
teleconference: the meeting will be
partially closed.
DATES: Thursday, March 29, 2007, from
2 p.m. until 3 p.m.
E:\FR\FM\15MRN1.SGM 15MRN1